Last updated: May 29, 2026
Duavee (conjugated estrogens plus bazedoxifene) is a branded combination product with a complex supply chain spanning estrogen conjugate processing, bazedoxifene API manufacture, and finished-dose tablet production. Supplier identification at the “who actually makes the finished drug” level depends on FDA drug-substance and drug-product listings and, for prescription products, often also on site-level manufacturing disclosures and labeling. With no specific US FDA product dossier, Orange Book listing set, or drug label manufacturer-to-site mapping provided here, only high-confidence supply categories can be stated without naming parties.
What suppliers make Duavee’s estrogen conjugates and bazedoxifene API?
Duavee’s active ingredients are:
- Conjugated estrogens (mixture of estrogens including equilin and equilein derivatives)
- Bazedoxifene (a SERM)
High-confidence supplier categories (API):
- Estrogen conjugate API processors that produce conjugated estrogen mixtures to USP/compendial specifications (mixture manufacture is typically vendor-specialized due to sourcing and fractionation steps).
- Bazedoxifene API manufacturers that run kilogram-to-multi-kilogram chemical synthesis, purification, and crystallization for bazedoxifene and provide quality-system release for GMP drug substance.
Key contracting pattern for combination brands
- Companies typically dual-source drug substance or lock single suppliers through quality agreements tied to the finished-dose NDA site.
- If a contract manufacturer produces the Duavee tablets, it typically buys APIs from qualified suppliers and performs blending, compression, and coating under a defined master batch record tied to the NDA.
Who manufactures Duavee tablets (finished-dose) and supplies packaging?
Finished-dose manufacturing and packaging typically sit with:
- Oral solid dose CMO/CDMO for tablet compression and film-coating (if Duavee’s tablet is film-coated).
- Primary packaging line suppliers for bottles/blisters and labeling application.
- Secondary packaging providers for cartons, leaflets, and distribution-ready kits.
Operational reality in branded oral solids
- Finished-dose sites are usually fixed for regulatory stability and supply continuity.
- Packaging supply is often more modular (bottles, labels, cartons) even when manufacturing is less flexible.
What is the Orange Book status of Duavee and how does it affect supplier switching?
Orange Book status governs exclusivity and generic entry risk, not day-to-day manufacturing supplier qualification. Still, it affects supplier strategy in two ways:
- Finished-dose suppliers for the NDA are incentivized to maintain continuity due to tight IP and regulatory documentation.
- Any attempt to switch sites or change suppliers can trigger comparability work and regulatory reporting requirements, especially for mixture products like conjugated estrogens.
If Duavee has listed patents and exclusivities in the US, that increases the value of maintaining the incumbent supply chain while blocking substitution by potential entrants.
Which companies can supply Duavee’s components without infringing Duavee patents?
Supplier feasibility is constrained by two layers:
- API IP: patents on conjugated estrogen compositions/processes and bazedoxifene synthesis or polymorph forms.
- Drug product IP: formulation, tablet composition, coating, dissolution profile, and manufacturing methods.
Practical supplier barrier
- Even if a CDMO can make the tablets, it still needs legal clearance on:
- exact formulation and excipients used in Duavee
- manufacturing process parameters tied to the NDA
- any polymorph/solid form commitments for bazedoxifene
When does Duavee lose exclusivity and does that open supplier opportunities?
The exclusivity and patent expiration timetable determines when:
- generic or AB-rated competitors can enter via ANDA
- “design-around” suppliers can produce alternative combinations or formulations without infringing
Supplier switching impacts
- Before entry: incumbent may keep one or two qualified sites to protect supply.
- After entry window: competition can increase, reducing raw material and CDMO pricing pressure and improving lead times.
How many suppliers exist for Duavee’s supply chain in practice?
For combination oral solid brands, a typical structure is:
- 1–2 qualified bazedoxifene API suppliers
- 1–2 qualified conjugated estrogens suppliers
- 1 primary and possibly 1 backup finished-dose manufacturing site
- Multiple packaging vendors (primary and secondary), qualified through stability and label control
This structure is consistent with GMP qualification risk management, but the actual count for Duavee depends on the NDA’s drug substance and drug product manufacturing disclosures.
What generic entry risks exist for Duavee that could change supplier demand?
Duavee’s combination nature creates specific risks for potential generics:
- bioequivalence challenges for fixed-dose estrogen/SERM combinations
- dissolution and formulation-specific comparability
- potential solid-form or process patents for bazedoxifene API
These risks can delay ANDA approvals and keep incumbent supplier demand steady longer than for simpler single-API products.
Key Takeaways
- Duavee’s supply chain splits into specialized drug substance suppliers for conjugated estrogens and bazedoxifene, plus one or more qualified oral solid manufacturing and packaging sites.
- Supplier switching is constrained less by commercial availability and more by NDA-linked quality agreements, comparability requirements, and patent- and formulation-protected details.
- Without the specific Duavee labeling/NDA manufacturing-site listing for the US product strength and dosage form, company-by-company supplier naming cannot be stated at the required accuracy level.
FAQs
- Which excipients and tablet-coating suppliers are typically used for Duavee?
- Can a CDMO make Duavee tablets using its own packaging line without NDA amendments?
- What are the main regulatory reporting triggers when switching conjugated estrogens or bazedoxifene API suppliers?
- Do Duavee patents cover manufacturing processes or only compositions?
- How do solid-form specifications for bazedoxifene affect API supplier qualification for combination products?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. United States.
- FDA. Drug Labeling and Prescribing Information for Duavee. United States.
- FDA. Approved Drug Products and Drug Substances (CDER Drug Registration and Listing System). United States.
